Company Overview of Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity and venture capital firm specializing in growth equity financing; incubation; expansion stage equity; recapitalizations; corporate divestitures, and carve-outs; leveraged recapitalizations; growth buyouts; spinouts; shareholder liquidity; startups, early stage investments including seed and Series A and B finan unmet medical needs cing rounds; late stage investments including Series C, D, mid venture, middle market, bridge financing, and PIPEs investments; and de novo investments across all stages of a company’s development. Within Life Science, it prefers to invest in drug development ranging from early-stage, pre-clinical opportunities, to la...
Two Union Square
601 Union Street
Seattle, WA 98101
Founded in 1991
Key Executives for Frazier Healthcare Partners
Founder, Managing Partner, Senior Advisor, and Chairman
Chief Financial Officer and Partner
General Partner, Managing General Partner, Founding General Partner, and Member of Management Committee
Compensation as of Fiscal Year 2016.
Frazier Healthcare Partners Key Developments
Frazier Healthcare Partners Appoints Brock Hardaway as an Operating Partner
Sep 7 16
Frazier Healthcare Partners announced that Brock Hardaway has joined the firm as an Operating Partner on the Growth Buyout team. He will assist the Growth Buyout team with identifying and executing opportunities in the post-acute sector. Brock most recently served as CEO of Millennium Health. In addition to clinical toxicology and under his leadership, the company developed a suite of genetic testing and predictive analytic products that armed healthcare providers with medication intelligence in an effort to improve medication effectiveness. Brock has also spent more than 23 years in various leadership and senior executive roles in the post-acute sector.
Frazier Healthcare Seeks Acquisitions
Jun 15 16
Frazier Healthcare Partners will comsider acquisitions. Frazier Healthcare has a $525 million health care buyout fund, which it closed in March 2016, and it is looking to buy companies with potential for fast earnings growth, increase those earnings and then sell the company or take it public.
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology
Mar 14 16
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced the formation of Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders. In exchange for undisclosed financial terms, Takeda has granted an exclusive license to Outpost for the worldwide development and commercialization rights to OP-233 (formerly TAK-233), a clinical-stage product candidate being studied for the treatment of stress urinary incontinence. In connection with the license, Outpost has completed a $41 million financing led by Frazier Healthcare Partners and including Adams Street Partners, Novo A/S, and Vivo Capital. Joining Tachi Yamada and David Socks on the Outpost board of directors are Dan Estes, Ph.D., Principal of Frazier Healthcare Partners, Terry Gould, Partner and Head of Direct Investments of Adams Street Partners, Peter Bisgaard, Senior Partner of Novo Ventures (US) Inc., and Chen Yu, M.D., Managing Partner of Vivo Capital.
Similar Private Companies By Industry
Recent Private Companies Transactions